166 related articles for article (PubMed ID: 24074031)
21. Lipid-based vehicle for oral drug delivery.
Stuchlík M; Zák S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2001 Dec; 145(2):17-26. PubMed ID: 12426768
[TBL] [Abstract][Full Text] [Related]
22. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.
Chen ML
Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051
[TBL] [Abstract][Full Text] [Related]
23. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
[TBL] [Abstract][Full Text] [Related]
24. Preclinical formulations for discovery and toxicology: physicochemical challenges.
Neervannan S
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):715-31. PubMed ID: 17014391
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Labrasol/Labrafil/Transcutol (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in Wistar rats.
Delongeas JL; de Conchard GV; Beamonte A; Bertheux H; Spire C; Maisonneuve C; Becourt-Lhote N; Goldfain-Blanc F; Claude N
Regul Toxicol Pharmacol; 2010; 57(2-3):284-90. PubMed ID: 20347907
[TBL] [Abstract][Full Text] [Related]
26. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.
Namdari R; Jones K; Chuang SS; Van Cruchten S; Dincer Z; Downes N; Mikkelsen LF; Harding J; Jäckel S; Jacobsen B; Kinyamu-Akunda J; Lortie A; Mhedhbi S; Mohr S; Schmitt MW; Prior H
Regul Toxicol Pharmacol; 2021 Nov; 126():105029. PubMed ID: 34455009
[TBL] [Abstract][Full Text] [Related]
27. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs.
Müllertz A; Ogbonna A; Ren S; Rades T
J Pharm Pharmacol; 2010 Nov; 62(11):1622-36. PubMed ID: 21039546
[TBL] [Abstract][Full Text] [Related]
28. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
29. The timing of preclinical toxicological studies: pharmaceutical company approaches to toxicity testing in support of initial clinical investigations.
Parkinson C; Thomas KE; Lumley CE
Regul Toxicol Pharmacol; 1996 Apr; 23(2):162-72. PubMed ID: 8661335
[TBL] [Abstract][Full Text] [Related]
30. Oral formulation strategies to improve solubility of poorly water-soluble drugs.
Singh A; Worku ZA; Van den Mooter G
Expert Opin Drug Deliv; 2011 Oct; 8(10):1361-78. PubMed ID: 21810062
[TBL] [Abstract][Full Text] [Related]
31. Toxicity of excipients--a Food and Drug Administration perspective.
Osterberg RE; See NA
Int J Toxicol; 2003; 22(5):377-80. PubMed ID: 14555410
[TBL] [Abstract][Full Text] [Related]
32. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs.
Gursoy RN; Benita S
Biomed Pharmacother; 2004 Apr; 58(3):173-82. PubMed ID: 15082340
[TBL] [Abstract][Full Text] [Related]
33. Strategy for genotoxicity testing--metabolic considerations.
Ku WW; Bigger A; Brambilla G; Glatt H; Gocke E; Guzzie PJ; Hakura A; Honma M; Martus HJ; Obach RS; Roberts S;
Mutat Res; 2007 Feb; 627(1):59-77. PubMed ID: 17141553
[TBL] [Abstract][Full Text] [Related]
34. In vitro - in vivo correlation: from theory to applications.
Emami J
J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
[TBL] [Abstract][Full Text] [Related]
35. Study designs for the nonclinical safety testing of new vaccine products.
Forster R
J Pharmacol Toxicol Methods; 2012 Jul; 66(1):1-7. PubMed ID: 22561062
[TBL] [Abstract][Full Text] [Related]
36. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
Buckley ST; Frank KJ; Fricker G; Brandl M
Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
[TBL] [Abstract][Full Text] [Related]
37. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
Wu Y; Loper A; Landis E; Hettrick L; Novak L; Lynn K; Chen C; Thompson K; Higgins R; Batra U; Shelukar S; Kwei G; Storey D
Int J Pharm; 2004 Nov; 285(1-2):135-46. PubMed ID: 15488686
[TBL] [Abstract][Full Text] [Related]
38. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
39. [Lipid vehicles for the parenteral administration of drugs (1): emulsions].
Bermejo Vicedo T; Hidalgo Correas FJ; Carrasco JM
Nutr Hosp; 1996; 11(1):7-16. PubMed ID: 8704021
[TBL] [Abstract][Full Text] [Related]
40. [Study on Chinese herbs' volatile oil micro-emulsions by means of pseudo-ternary phase diagram].
Yang MM; Zhang Y; Liu XY; Zhang TT; Liu M
Zhong Yao Cai; 2011 Aug; 34(8):1288-92. PubMed ID: 22233047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
